Discovery and validation of PZP as a novel serum biomarker for screening lung adenocarcinoma in type 2 diabetes mellitus patients.

Jiayue YangCheng YangHong ShenWenjun WuZhen TianQinghua XuCuiping CaoShugao YeLe BanXin TongJie Mei

Published in: Cancer cell international (2021)

Our findings indicated that PZP could be used as a novel serum biomarker for the identification of LAC in T2DM patients, which will enhance auxiliary diagnosis and assist in the selection of surgical treatment at an early stage.

Keyphrases

end stage renal disease
early stage
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
type diabetes
squamous cell carcinoma
small molecule
radiation therapy
high throughput
lymph node
rectal cancer
sentinel lymph node
bioinformatics analysis